Table 1.
Inhaled antimicrobials marketed or undergoing clinical trials for treatment of P. aeruginosa infections in CF patients. Adapted from [2,43].
| Drug | Product Name | Development Status | Formulation |
|---|---|---|---|
| Tobramycin | Tobi®, Bramitob® | Marketed | LF, DP |
| Levofloxacin | Aeroquin® | Phase III (NCT01270347, NCT01180634) * | LF |
| Aztreonam lysine | Cayston® | Marketed | LF |
| Colistimethate sodium | Promixin®, Colobreathe® | Marketed | LF, DP |
| Azithromycin | Zithromax® | Marketed | |
| Amikacin | Arikayce™ | Phase III (NCT01315678) * | LF |
| Ciprofloxacin | Cipro Inhale® | Phase II (NCT00645788) * | DP |
LF: Liquid formulation, DP: Dry powder. * More information on clinicaltrials.gov.